Opko Acquires Curna for $10M

Premium

Opko Health said this week that it has acquired Curna, an early-stage developer of non-coding RNA-based treatments for cancer, heart disease, metabolic disorders, and genetic anomalies.

Curna's technology, according to Opko, allows for the up-regulation of target proteins and was exclusively licensed from the Scripps Research Institute.

According to a filing with the US Securities and Exchange Commission, Opko acquired all outstanding shares of privately held Curna for $10 million in cash.

Additional terms were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Genome Research this week: methylation patterns in multiple myeloma, recent Y chromosome bottleneck, and more.

By studying the spectra of microbes on Earth, a team of researchers hopes to be better equipped to detect any on other worlds.

SolveBio's Mark Kaganovich says at TechCrunch that genomics needs an app to push it into the mainstream.

A University of Michigan team is using a Facebook app to recruit and keep in touch with participants in its 'Genes for Good' project.